Stopping Metoprolol: Why the Last Dose Needs a Plan

Evidence review updated August 29, 2026 using current U.S. prescribing information, cardiovascular guidelines, and primary discontinuation studies. Medical review is pending.

First separate two questions that sound like one

If you opened this page because metoprolol makes you tired, dizzy, or unable to exercise the way you used to, “Can I stop?” is a fair question. It is also two different questions:

1. Does metoprolol still have an important job in my treatment?
2. If that job has changed, how should exposure be reduced without creating avoidable risk?

Evidence that some people no longer benefit from indefinite beta-blocker therapy does not make sudden withdrawal safe. Conversely, a warning against abrupt withdrawal does not mean every person needs metoprolol forever. The decision about duration and the method of discontinuation need separate answers.

That distinction is the center of this guide. The former page blurred the two and supplied an invented “halve every five to seven days” rule as though every indication, dose, and formulation were interchangeable.

What the FDA warning says—and what it does not

The current metoprolol succinate label says that after abrupt cessation of certain beta-blockers, worsening angina and, in some cases, myocardial infarction have occurred. For chronically administered metoprolol, particularly in ischemic heart disease, it directs gradual dose reduction over 1 to 2 weeks with monitoring [1]. The tartrate label carries the same warning [2]. Both add an easily missed point: coronary artery disease is common and may be unrecognized, so abrupt discontinuation should be avoided even when metoprolol was prescribed only for hypertension.

The label's time window is the most authoritative general boundary available. The actual dose steps still depend on the starting dose, formulation and tablet strength, indication, symptoms, other rate-slowing medicines, and the clinician's response plan. This page cannot safely convert that into a personal taper.

The Indication–Exposure–Exit Record

A stopping plan is not complete until it can fill all four rows below. This is more useful than copying a dose ladder from someone who takes metoprolol for a different reason.

If “Job” is blank, checking the prescription history or asking the original prescriber is more important than calculating the next smaller dose.

The reason you take metoprolol changes what is at stake

Angina, coronary disease, or a prior heart attack

Metoprolol reduces heart rate and myocardial oxygen demand. Stopping can both reveal the symptoms it was suppressing and produce a period of heightened beta-adrenergic responsiveness. New chest pressure after a dose change is therefore not something to diagnose at home as “just withdrawal.”

Long-term use after an uncomplicated myocardial infarction is now more nuanced than it once was. The 2023 chronic coronary disease guideline says long-term beta-blocker therapy is not recommended solely to improve outcomes when there has been no MI in the past year, left ventricular ejection fraction is above 50%, and there is no other primary indication [3]. But angina, uncontrolled hypertension, an arrhythmia, or reduced ventricular function can still be reasons to continue.

Two modern discontinuation trials also reached different answers. In the 2024 ABYSS trial, interruption was not shown noninferior to continuation in 3,698 stable post-MI patients with ejection fraction of at least 40%; the primary outcome occurred in 23.8% versus 21.1%, and quality of life did not improve [4]. In the 2026 SMART-DECISION trial, discontinuation was noninferior among 2,540 stable South Korean patients who had taken a beta-blocker for at least one year after MI, had ejection fraction of at least 40%, and had no heart failure [5].

The honest synthesis is not “beta-blockers are obsolete after a heart attack.” It is that continued benefit depends on patient selection and other indications. Both trials studied planned clinical strategies in selected, stable patients—not abruptly running out of metoprolol at home.

Heart failure with reduced ejection fraction

Metoprolol succinate extended-release is one of the beta-blockers with outcome evidence in HFrEF. The 2022 AHA/ACC/HFSA guideline recommends an evidence-based beta-blocker to reduce mortality and hospitalization and warns that abrupt withdrawal can cause clinical deterioration [6].

Registry evidence cannot prove that withdrawal itself caused every bad outcome, because sicker patients are more likely to have treatment stopped. Still, the signal is sobering: in OPTIMIZE-HF, withdrawal during hospitalization for systolic heart failure was associated with higher adjusted post-discharge mortality than continuation (hazard ratio 2.3; 95% CI 1.2–4.6) [7]. That study examined a hospitalized, decompensated population and should not be applied as an individual risk estimate for a stable outpatient. It does show why “my blood pressure looks normal” is not enough to decide that a heart-failure drug has finished its job.

The investigators' own conclusion is appropriately narrower than a universal warning: “withdrawal of beta-blocker therapy is associated with worse risk and propensity-adjusted mortality.” Fonarow and colleagues were describing the hospitalized OPTIMIZE-HF cohort—not endorsing a single outpatient taper or predicting one person's outcome [7].

For formulation and indication differences, see the broader metoprolol guide and the metoprolol-versus-carvedilol comparison.

Rate or rhythm control

For atrial fibrillation, supraventricular tachycardia, or another tachyarrhythmia, a comfortable resting pulse may be evidence that metoprolol is working—not evidence that the underlying rhythm issue is gone. The exit plan needs to say whether another rate-control strategy is replacing it and how recurrent palpitations or a fast rhythm will be assessed.

Hypertension without a known cardiac indication

The immediate danger is generally less predictable than in active angina or HFrEF, but that does not make a cold stop evidence-based. Blood pressure may rise as medication effect is removed, and unrecognized coronary disease is the reason the FDA warning explicitly extends caution to hypertension-only treatment.

Home readings are most useful when collected consistently with a validated upper-arm cuff and interpreted as a pattern. A single normal reading while taking metoprolol does not show what pressure will be without it.

Hyperthyroidism and surgery are special contexts

The succinate label warns that abruptly withdrawing beta-blockade can precipitate thyroid storm in thyrotoxicosis [1]. It also says chronic beta-blocker therapy should not be routinely withdrawn before major surgery. A surgery date is therefore a medication-reconciliation prompt, not a reason to stop the night before unless the surgical or anesthesia team specifically directs it.

What withdrawal studies really measured

The direct metoprolol withdrawal literature is small and old, which makes precision especially important.

In a 1982 study, only eight people taking a very high historical dose—300 mg/day for essential hypertension—were switched abruptly to placebo. Between days 2 and 8, resting heart rate rose an average of 15% and beta-adrenergic sensitivity increased 52%. No associated arrhythmia appeared on Holter monitoring; one person had a transient blood-pressure increase and three reported withdrawal-like symptoms. A later low-dose phase reduced but did not eliminate the measured rebound [8].

In a 1984 post-MI study, 115 people had metoprolol or placebo withdrawn gradually over one week. Disabling symptoms requiring treatment to be restarted occurred in 14 of 58 people withdrawing metoprolol versus 4 of 57 withdrawing placebo. Basal and standing-response heart rates remained elevated during the first three weeks [9].

These studies support a real rebound phenomenon, but they do not justify claims that everyone develops symptoms within 24–72 hours, that pressure rises by a fixed number, or that cutting the dose by exactly 50% prevents the problem. The sample sizes, doses, era, and patient populations do not support that certainty. The FDA's 1-to-2-week gradual-reduction warning remains the general rule; individual steps remain individual.

Withdrawal or the original condition returning?

The two can overlap:

• A faster pulse may reflect transient adrenergic sensitivity, recurrence of a rhythm problem, pain, dehydration, infection, thyroid disease, or several of these.
• Higher blood pressure may reflect removal of antihypertensive effect, inconsistent measurement, another medicine such as a decongestant or NSAID, or true rebound.
• Chest discomfort can be recurrent angina, acute coronary ischemia, or a noncardiac cause. The dangerous possibilities must be assessed rather than labeled from a webpage.
• Shortness of breath may reflect recurrent rate problems, heart-failure congestion, bronchospasm, anxiety, or another illness.

That diagnostic ambiguity is why a plan needs baseline measurements, a known indication, and a response route—not simply a countdown to the final pill.

If you missed a dose or ran out

One missed dose is not the same as a planned discontinuation, and it should not be “repaired” with extra tablets. Current succinate and tartrate labels tell patients to take only the next scheduled dose and not double [1,2]. Follow the instructions supplied with your own product and contact the pharmacist or prescriber if the gap is longer, the directions are unclear, or you take metoprolol for angina, heart failure, or rhythm control.

If access is the problem, say that directly when calling. A refill bridge and an elective decision to deprescribe are different problems and should not be forced into the same solution.

When the plan should become urgent

New or worsening chest pressure, severe shortness of breath, fainting, new weakness or difficulty speaking, or another possible heart attack or stroke symptom requires emergency evaluation. Marked palpitations, a sustained change in pulse or blood pressure, worsening swelling or breathlessness in heart failure, or symptoms of very low heart rate or pressure merit prompt clinician contact according to the plan you were given.

Conversely, adverse effects while still taking metoprolol can sometimes require a same-day hold or urgent treatment. Severe bradycardia, hypotension, heart block, decompensated heart failure, or a serious breathing reaction are not situations for a generic internet taper. The clinician assessing the event has to balance the immediate drug effect against withdrawal and the untreated indication.

For related questions, the metoprolol onset guide explains why tartrate and succinate do not produce identical exposure curves, while the beta-1 selectivity guide explains what “cardioselective” does—and does not—mean.

What was removed from the former page